Table 4B.

Risks of hospitalized heart failure associated with cilostazol and NSAIDs use on different window lengths of case period and control period (N = 47,506).

	Case period 1-60 days		Case period 1-60 days		Case period 1-90 days		Case period 1-90 days
	before index date		before index date		before index date		before index date
	Control period 61-120 days		Control period 91-150 days		Control period 91-180 days		Control period 121-210 days
	before index date		before index date		before index date		before index date
	Adjusted∗ OR	95% C.I.	Adjusted∗ OR	95% C.I.	Adjusted∗ OR	95% C.I.	Adjusted∗ OR	95% C.I.
Cilostazol	1.54	1.27–1.88	1.31	1.12–1.54	1.09	0.93–1.27	1.06	0.92–1.21
NSAIDs	1.51	1.45–1.58	1.45	1.39–1.50	1.33	1.28–1.38	1.26	1.22–1.31

^∗Conditional logistic regression adjusted for important potential time-varying confounding variables including pioglitazone, metformin, sitagliptin, aspirin, angiotensin converting enzyme inhibitors, beta-blockers, calcium channel blockers, diuretics, nitrates, digitalis glycoside, inhaled beta-agonists, inhaled anticholinergics, aminophylline, oral corticosteroids, and systemic antibiotics. Bold values indicate statistical significance; OR, odds ratio; 95% C.I., confidence interval.